![]() ![]() He also commented that “ large possible confounding variable in this study is whether those who were taking PDE5 inhibitors could also be engaging in increased sexual activity and that the sexual activity itself was lending to the benefit, independent of the effects of the drug.” “illing a medication does not necessarily equal taking the medication,” cautioned Dr. The authors also note that the retrospective nature of the study prevents them from establishing the cause of the link and that the exposure to PDE-5i is estimated from tables dispensed which may not be accurate as tablets may not have been taken or may have also been obtained from another source. The research team explained this may be due to the small number of participants in the subgroups. Men with type 2 diabetes receiving PDE-5i medication also recorded a lower incidence of MACE, as did men diagnosed with CAD but the trend was nonsignificant. “ED medications are being increasingly prescribed ” he noted, and “taken as needed, while cardiac therapies are typically taken regularly, so the assumption is that the level of exposure to PDE5 inhibition may not be all that high.” Rigved Tadwalkar, a board-certified cardiologist at Providence Saint John’s Health Center in Santa Monica who was not involved in the study told MNT that prescriptions for ED medications are on the increase. They should only be used for the treatment of ED or pulmonary hypertension, on label, at the recommended dose levels.”ĭr. In addition, we are not suggesting that PDE-5 inhibitors be used off-label. However, our study was a retrospective study and until a prospective, placebo-controlled study of various doses is performed we cannot recommend doses. “We did find a greater benefit on MACE with higher doses. Speaking to Medical News Today, study lead author Dr. The reduction in MACE, heart attacks, and stroke was greatest in men who took the largest amount of these drugs over the study period, with a 55% reduction in MACE and a 49% reduction in overall mortality observed. ![]() Similar reduced major adverse cardiac events (MACE) - cardiovascular-related death, hospitalization for heart attack, coronary revascularization, stroke, heart failure, and unstable angina - and mortality findings occurred in participants without CAD but with known cardiovascular disease risk factors who had been exposed to PDE-5i. Overall mortality was reduced by 25% in men exposed to PDE-5i and the team recorded a 39% lower risk of dying due to cardiovascular-related causes. The research team found men taking PDE-5i drugs were 13% less likely to suffer a cardiac event, this was linked to a reduction in coronary revascularisation, heart failure, and unstable angina. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |